Pneumococcal Disease Prevention: Are We on the Right Track?
Abstract
:1. Background
2. From the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to the 10-Valent (PCV10) and 13-Valent (PCV13) Vaccines
3. Limitations of Pneumococcal Prevention
4. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Esposito, S.; Principi, N.; ESCMID Vaccine Study Group. Direct and indirect effects of the 13-valent pneumococcal conjugate vaccine administered to infants and young children. Future Microbiol. 2015, 10, 1599–1607. [Google Scholar] [CrossRef]
- Dobay, O. The complexity of serotype replacement of pneumococci. Hum. Vaccin. Immunother. 2019, 15, 2725–2728. [Google Scholar] [CrossRef]
- Weinberger, D.M.; Malley, R.; Lipsitch, M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011, 378, 1962–1973. [Google Scholar] [CrossRef] [Green Version]
- Mrkvan, T.; Pelton, S.I.; Ruiz-Guiñazú, J.; Palmu, A.A.; Borys, D. Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: Review of clinical trials and post-marketing experience. Expert Rev. Vaccines 2018, 17, 797–818. [Google Scholar] [CrossRef]
- Principi, N.; Di Cara, G.; Bizzarri, I.; Isidori, C.; Borgia, P.; Mignini, C.; Saponara, M.; Argentiero, A.; Esposito, S. Prevention of Invasive Pneumococcal Disease: Problems Emerged After Some Years of the 13-Valent Pneumococcal Conjugate Vaccine Use. Curr. Infect. Dis. Rep. 2018, 20, 1. [Google Scholar] [CrossRef]
- Platt, H.L.; Greenberg, D.; Tapiero, B.; Clifford, R.A.; Klein, N.P.; Hurley, D.C.; Shekar, T.; Jianing, L.; Hurtado, K.; Su, S.C.; et al. A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. Pediatr. Infect. Dis. J. 2020, 39, 763–770. [Google Scholar] [CrossRef]
- Thompson, A.; Lamberth, E.; Severs, J.; Scully, I.; Tarabar, S.; Ginis, J.; Jansen, K.U.; Gruber, W.C.; Scott, D.A.; Watson, W. Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 2019, 37, 6201–6207. [Google Scholar] [CrossRef]
- Masomian, M.; Ahmad, Z.; Gew, L.T.; Poh, C.L. Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection. Vaccines 2020, 8, 132. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Corsini, B.; Aguinagalde, L.; Ruiz, S.; Domenech, M.; Antequera, M.L.; Fenoll, A.; García, P.; García, E.; Yuste, J. Immunization with LytB protein of Streptococcus pneumoniae activates complement-mediated phagocytosis and induces protection against pneumonia and sepsis. Vaccine 2016, 34, 6148–6157. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tarancón, R.; Domínguez-Andrés, J.; Uranga, S.; Ferreira, A.V.; Groh, L.A.; Domenech, M.; González-Camacho, F.; Riksen, N.P.; Aguilo, N.; Yuste, J.; et al. New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumonia. PLoS Pathog. 2020, 16, e1008404. [Google Scholar] [CrossRef] [PubMed]
- Langereis, J.D.; de Jonge, M.I. Non-encapsulated Streptococcus pneumoniae vaccination as a measure to interfere with horizontal gene transfer. Virulence 2017, 8, 637–639. [Google Scholar] [CrossRef] [Green Version]
- Anderson, R.; Nel, J.G.; Feldman, C. Multifaceted Role of Pneumolysin in the Pathogenesis of Myocardial Injury in Community-Acquired Pneumonia. Int. J. Mol. Sci. 2018, 19, 1147. [Google Scholar] [CrossRef] [Green Version]
- Sings, H.L.; De Wals, P.; Gessner, B.D.; Isturiz, R.; Laferriere, C.; McLaughlin, J.M.; Pelton, S.; Schmitt, H.F.; Suaya, J.A.; Jodar, L. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-analysis of Observational Studies. Clin. Infect. Dis. 2019, 68, 2135–2143. [Google Scholar] [CrossRef]
- McLaughlin, J.M.; Jiang, Q.; Gessner, B.D.; Swerdlow, D.L.; Sings, H.L.; Isturiz, R.E.; Jodar, L. Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis. Vaccine 2019, 37, 6310–6316. [Google Scholar] [CrossRef]
- de Miguel, S.; Domenech, M.; González-Camacho, F.; Sempere, J.; Vicioso, D.; Sanz, J.C.; Comas, L.G.; Ardanuy, C.; Fenoll, A.; Yuste, J. Nationwide trends of invasive pneumococcal disease in Spain (2009–2019) in children and adults during the pneumococcal conjugate vaccine era. Clin. Infect. Dis. 2020. [Google Scholar] [CrossRef]
- Andrews, N.; Kent, A.; Amin-Chowdhury, Z.; Sheppard, C.; Fry, N.; Ramsay, M.; Ladhani, S.N. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006–2018. Vaccine 2019, 37, 4491–4498. [Google Scholar] [CrossRef] [PubMed]
- Domínguez, Á.; Ciruela, P.; Hernández, S.; García-García, J.J.; Soldevila, N.; Izquierdo, C.; Moraga-Llop, F.; Díaz, A.; de Sevilla, M.F.; González-Peris, S.; et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study. PLoS ONE 2017, 12, e0183191. [Google Scholar]
- Slotved, H.C.; Dalby, T.; Harboe, Z.B.; Valentiner-Branth, P.; Casadevante, V.F.; Espenhain, L.; Fuursted, K.; Bossen Konradsen, H. The incidence of invasive pneumococcal serotype 3 disease in the Danish population is not reduced by PCV-13 vaccination. Heliyon 2016, 2, e00198. [Google Scholar] [CrossRef] [Green Version]
- Fukusumi, M.; Chang, B.; Tanabe, Y.; Oshima, K.; Maruyama, T.; Watanabe, H.; Kuronuma, K.; Kasahara, K.; Takeda, H.; Nishi, J.; et al. Adult IPD Study Group. Invasive pneumococcal disease among adults in Japan, April 2013 to March 2015: Disease characteristics and serotype distribution. BMC Infect. Dis. 2017, 17, 2. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Carloni, I.; Ricci, S.; Rubino, C.; Cobellis, G.; Rinaldelli, G.; Azzari, C.; de Benedictis, F.M. Necrotizing pneumonia among Italian children in the pneumococcal conjugate vaccine era. Pediatr. Pulmonol. 2021. [Google Scholar] [CrossRef]
- Goettler, D.; Streng, A.; Kemmling, D.; Schoen, C.; von Kries, R.; Rose, M.A.; van der Linden, M.; Liese, J.G. Increase in Streptococcus pneumoniae serotype 3 associated parapneumonic pleural effusion/empyema after the introduction of PCV13 in Germany. Vaccine 2020, 38, 570–577. [Google Scholar] [CrossRef] [PubMed]
- Syrogiannopoulos, G.A.; Michoula, A.N.; Tsimitselis, G.; Vassiou, K.; Chryssanthopoulou, D.C.; Grivea, I.N. Pneumonia with empyema among children in the first five years of high coverage with 13-valent pneumococcal conjugate vaccine. Infect. Dis. 2016, 48, 749–753. [Google Scholar] [CrossRef] [PubMed]
- Strachan, R.; Homaira, N.; Beggs, S.; Bhuiyan, M.U.; Gilbert, G.L.; Lambert, S.B.; Macartney, K.; Marshall, H.; Martin, A.C.; McCallum, G.B.; et al. Assessing the impact of the 13 valent pneumococcal vaccine on childhood empyema in Australia. Thorax 2021. [Google Scholar] [CrossRef]
- Luck, J.N.; Tettelin, H.; Orihuela, C.J. Sugar-Coated Killer: Serotype 3 Pneumococcal Disease. Front. Cell Infect. Microbiol. 2020, 10, 613287. [Google Scholar] [CrossRef]
- Choi, E.H.; Zhang, F.; Lu, Y.J.; Malley, R. Capsular Polysaccharide (CPS) Release by Serotype 3 Pneumococcal Strains Reduces the Protective Effect of Anti-Type 3 CPS Antibodies. Clin. Vaccine Immunol. 2015, 23, 162–167. [Google Scholar] [CrossRef] [Green Version]
- Andrews, N.J.; Waight, P.A.; Burbidge, P.; Pearce, E.; Roalfe, L.; Zancolli, M.; Slack, M.; Ladhani, S.N.; Miller, E.; Goldblatt, D. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: A postlicensure indirect cohort study. Lancet Infect. Dis. 2014, 14, 839–846. [Google Scholar] [CrossRef]
- Principi, N.; Esposito, S. Development of pneumococcal vaccines over the last 10 years. Expert Opin. Biol. Ther. 2018, 18, 7–17. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Principi, N.; Esposito, S. Pneumococcal Disease Prevention: Are We on the Right Track? Vaccines 2021, 9, 305. https://doi.org/10.3390/vaccines9040305
Principi N, Esposito S. Pneumococcal Disease Prevention: Are We on the Right Track? Vaccines. 2021; 9(4):305. https://doi.org/10.3390/vaccines9040305
Chicago/Turabian StylePrincipi, Nicola, and Susanna Esposito. 2021. "Pneumococcal Disease Prevention: Are We on the Right Track?" Vaccines 9, no. 4: 305. https://doi.org/10.3390/vaccines9040305